| Document |
Document Title |
|
WO/2023/110867A1 |
The invention relates to a process for the preparation of the gadolinium dimeric contrast agent [p-[l-[bis[2-(hydroxy-KO)-3-[4,7,10-tris[(carboxy-KO)methyl]
-l,4,7,10- tetraazacyclododec-l-yl-K/V1,K/V4,K/V7,K/V10]propyl]amino]-l
-deoxy-D...
|
|
WO/2023/110863A1 |
The present invention relates to a process for the manufacturing of a mixture comprising the intermediate 1-[bis[2-hydroxy-3-[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxo
ethyl]-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1-deox
y-D-gluci...
|
|
WO/2023/104941A1 |
The invention relates to the field of bioconjugation of functional entities (payloads) to targeting agents, in particular biological targeting agents, such as antibody drug conjugates (ADCs), where one or more payload molecules are conju...
|
|
WO/2023/098072A1 |
Provided are a Nectin-4-targeted bicyclic peptide nuclide ligand and probe. The ligand has a structure represented by formula I, where X is Lys or Arg; and R is a group represented by formula II, formula III, formula IV or formula V. The...
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/097386A1 |
The present invention relates to selective HDAC6-inhibiting N-acylhydrazone compounds. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), and to the methods for producing same, compositions, kit...
|
|
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
|
WO/2023/070202A1 |
Compounds, e.g., radioimmunoconjugates including a chelating moiety or a metal complex thereof, a linker, and an Claudin 18.2 targeting moiety. Pharmaceutical compositions of such compounds and methods of treatment for conditions, e.g., ...
|
|
WO/2022/261467A9 |
Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.
|
|
WO/2023/066784A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to met...
|
|
WO/2023/052309A1 |
The present disclosure relates to a process for manufacturing at least one sartan active compound of formula (I) wherein R is selected from a group of formulas (1), (2), (3), (4) and (5), comprising the tetrazolylation of one compound of...
|
|
WO/2023/046836A1 |
The present application relates to a process for purifying a tetrazole-containing-sartan or a tetrazole-containing-sartan intermediate, the process comprising the steps of (a) providing a composition comprising an azide-impurity together...
|
|
WO/2023/045910A1 |
The present application discloses a small-molecule compound having a naphthol ether structure, and a use thereof. Disclosed in the present application are a compound having a structure represented by general formula (I), a pharmaceutical...
|
|
WO/2023/043803A1 |
Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclose...
|
|
WO/2023/006721A1 |
The invention relates to a process for the preparation of dimeric contrast agents foruse in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-κO)-3-[4,7,10-tris[(carboxy-κO)meth
yl]-1,4,7,10-tetraazacyclododec-1-yl...
|
|
WO/2023/007188A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or pol...
|
|
WO/2023/285344A1 |
The present invention relates to an improved crystal form of SCO-101, its preparation and use. Further, the invention relates to intermediary crystal forms of SCO-101 that can be converted to the improved crystal form of SCO-101.
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2022/258040A1 |
Provided is a heterocyclic compound for a TEAD inhibitor. The heterocyclic compound has the structure shown in formula I, and the groups in formula I are defined as described herein. The heterocyclic compound is used for preventing and/o...
|
|
WO/2022/248587A1 |
The invention relates to a novel amino acid having a tetrazine moiety and peptide or protein comprising the novel amino acid compounds. The invention also relates to a method of producing peptide or proteins comprising a tetrazine moiety...
|
|
WO/2022/238247A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as defined herein. The invention further relates to compositions comprising said compounds, to method...
|
|
WO/2022/233727A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to met...
|
|
WO/2022/224195A1 |
The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones,...
|
|
WO/2022/224212A1 |
The disclosures herein relate to novel compounds of formula (1): (1) and salts and any tautomers thereof, wherein X, R1 and R2 are defined herein, and their use 5 in treating, preventing, ameliorating, controlling or reducing the risk of...
|
|
WO/2022/219546A1 |
The present application relates to Leukotriene A4 hydrolase (LTA4H) inhibitors of formula (I), for use in the treatment of various disorders.
|
|
WO/2022/206862A1 |
A compound represented by formula (I) and a pharmaceutically acceptable salt thereof, as well as an antifungal application of the compound.
|
|
WO/2022/207425A1 |
The present invention relates to a process for the preparation of Cyclen, in its turn widely employed in the manufacturing of a variety of macrocyclic gadolinium complexes for use as MRI contrast agents. The said process comprises an eff...
|
|
WO/2022/194777A1 |
The present invention relates to a new class of compounds of general formula (I), the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. Formula (I)
|
|
WO/2022/187200A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a of RNR inhibitor disclosed herein.
|
|
WO/2022/186311A1 |
The compound according to the present invention has, within its structure, a chelate moiety that can coordinate with a radioactive metal ion, a first atomic group including an albumin binding site, and a second atomic group including a b...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/172994A1 |
The present invention provides a method for producing an oligonucleotide having a phosphate ester bond by oxidizing an oligonucleotide precursor having a phosphite ester bond or a phosphonic acid ester bond via an oxidizing agent, wherei...
|
|
WO/2022/173904A1 |
The present invention provides a pharmaceutical composition comprising the compound of any the present invention and a pharmaceutically acceptable carrier. The present invention provides a method for stabilizing TTR tetramers in a mammal...
|
|
WO/2022/166990A1 |
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...
|
|
WO/2022/164857A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N -oxides, and salts thereof, Wherein R1, R2, R3, A, X and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...
|
|
WO/2022/155171A1 |
Formation of methanoic acid, during the production of Hexahydro-1,3,5-trinitro-1,3,5- triazine and Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine via the legacy Bachmann nitrolysis process, is avoided when the workup is performed under...
|
|
WO/2022/038365A9 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
|
|
WO/2022/142534A1 |
Disclosed in the present invention are a tetrazine compound, a preparation method therefor, and an application thereof. The tetrazine compound provided by the present invention can be used for implementing selective tetrazine labeling of...
|
|
WO/2022/133537A1 |
This disclosure relates to compounds that include a first chelating ligand selective for 89Zr linked by a linker group to a second chelating ligand selective for a radionuclide other than 89Zr. Also disclosed are complexes, pharmaceutica...
|
|
WO/2022/138703A1 |
Provided is a gas-generating agent that generates a gas through the radiation of light. The gas-generating agent comprises: a gas-generating moiety having a specific structure; and a fluorinated aliphatic hydrocarbon group, which may con...
|
|
WO/2022/129724A1 |
The present invention relates to a sequential one-pot synthesis of TKX-50, suitable for larger-scale production, during which an acetyl halide is used during the cyclization of diazidoglyoxime so as to obtain 1,1'-diacetyl-5,5'-bistetraz...
|
|
WO/2022/132924A1 |
The present invention provides novel compounds: (I), and (II) methods of making such compounds, methods of using such compounds for pretargeted imaging, and preparations of formulations for such use.
|
|
WO/2022/126275A1 |
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.
|
|
WO/2022/129125A1 |
The present invention related to compounds of Formula (I):(I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to...
|
|
WO/2022/129508A1 |
The present invention concerns a family of organometallic compounds of formula (I) and its use to obtain contrast media applicable in various diagnostic imaging techniques such as X-ray, MRI, PET or SPECT or combinations of these techniq...
|
|
WO/2022/122035A1 |
Provided are a coagulation factor XIa inhibitor, a preparation method, a pharmaceutical composition and the use thereof for preventing or treating diseases related to the activity of FXIa. Specifically, provided are an amide derivative a...
|
|
WO/2022/120353A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/117619A1 |
The invention relates to a process for preparing Gadoteridol of formula (I).In particular, the process comprises the use of propylene oxide in the alkylation step of the compound of formula (II), wherein propylene oxide is directly react...
|
|
WO/2022/117877A1 |
The present invention provides cyclic tetrapeptides consisting of alternating α- and β-amino acids and metal complexes thereof. The cyclic tetrapeptides are particularly useful for coordinating a metal selected from Pb, Cd, Hg and As. ...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
